These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1847387)

  • 1. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.
    Hansen L; Blue Y; Barone K; Collen D; Larsen GR
    J Biol Chem; 1988 Oct; 263(30):15713-9. PubMed ID: 3139674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
    Matsuno H; Uematsu T; Nakashima M
    Br J Pharmacol; 1993 Dec; 110(4):1278-9. PubMed ID: 8306063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
    Larsen GR; Henson K; Blue Y
    J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes.
    Lee SG; Kalyan N; Wilhelm J; Hum WT; Rappaport R; Cheng SM; Dheer S; Urbano C; Hartzell RW; Ronchetti-Blume M
    J Biol Chem; 1988 Feb; 263(6):2917-24. PubMed ID: 3125172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
    Verheijen JH; Caspers MP; Chang GT; de Munk GA; Pouwels PH; Enger-Valk BE
    EMBO J; 1986 Dec; 5(13):3525-30. PubMed ID: 3030730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
    J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
    Collen D; Stassen JM; Larsen G
    Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
    Berg DT; Burck PJ; Berg DH; Grinnell BW
    Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
    Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
    Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
    Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.